Spero Therapeutics, Inc. Quarterly Debt-to-equity in % from Q2 2018 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Spero Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q2 2018 to Q2 2024.
  • Spero Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 80 %, a 5.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 80 +4.24 +5.6% Jun 30, 2024
Q1 2024 78.4 +3.74 +5.01% Mar 31, 2024
Q4 2023 78.8 -14 -15.1% Dec 31, 2023
Q3 2023 77.9 -25.2 -24.4% Sep 30, 2023
Q2 2023 75.7 -0.19 -0.25% Jun 30, 2023
Q1 2023 74.7 +10 +15.5% Mar 31, 2023
Q4 2022 92.8 +51.4 +124% Dec 31, 2022
Q3 2022 103 +79.2 +332% Sep 30, 2022
Q2 2022 75.9 +54.9 +261% Jun 30, 2022
Q1 2022 64.7 +44.1 +214% Mar 31, 2022
Q4 2021 41.4 +18.4 +79.8% Dec 31, 2021
Q3 2021 23.9 -5.59 -19% Sep 30, 2021
Q2 2021 21 -10.6 -33.6% Jun 30, 2021
Q1 2021 20.6 -4.86 -19.1% Mar 31, 2021
Q4 2020 23 +3.74 +19.4% Dec 31, 2020
Q3 2020 29.5 +16.3 +123% Sep 30, 2020
Q2 2020 31.6 +21.3 +206% Jun 30, 2020
Q1 2020 25.4 +15.4 +154% Mar 31, 2020
Q4 2019 19.3 +9.62 +99.5% Dec 31, 2019
Q3 2019 13.2 +3.99 +43.4% Sep 30, 2019
Q2 2019 10.3 -9.96 -49.1% Jun 30, 2019
Q1 2019 10 Mar 31, 2019
Q4 2018 9.67 Dec 31, 2018
Q3 2018 9.2 Sep 30, 2018
Q2 2018 20.3 Jun 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.